337526-59-7

Upstream product

• 826-73-3 1-Benzosuberone 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 870679-56-4 ethyl γ-(1-oxo-2,3,4,5-tetrahydrobenzocyclohepten-2-yl)-α-oxoacetate 
• 337526-58-6 ethyl 1-(2',4'-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxylate 

Downstream Products

• 494844-04-1 N-piperidin-1-yl-1-(2′,4′-dichlorophenyl)-8-nitro-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 
• 494844-05-2 N-piperidin-1-yl-1-(2′,4′-dichlorophenyl)-9-nitro-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 
• 494844-16-5 1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-9-nitro-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 
• 494844-15-4 1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-8-nitro-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 
• 1026536-00-4 9-amino-1-(2,4-dichloro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulene-3-carboxylic acid azepan-1-ylamide 
• 1027966-04-6 8-amino-1-(2,4-dichloro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulene-3-carboxylic acid azepan-1-ylamide 
• 494844-06-3 8-amino-1-(2,4-dichloro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulene-3-carboxylic acid piperidin-1-ylamide 

Relevant academic research and scientific papers

Pharmaceutical compounds wiht angiogenesis inbhibitory activity

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A' are as defined in the description. B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3-, SO3H, COO-, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

PHARMACEUTICAL COMPOUNDS

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A′ are as defined in the description.B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3?, SO3H, COO?, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′, 4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7] cyclohepta[1,2-c]pyrazole-3-carboxamide

A series of analogues of 8-chloro-1-(2′,4′-dichlorophenyl)-AT- piperidin-1-yl-1,4,5,6-tetrahydrobenzo-[6,7]cyclohepta[1,2-c] pyrazole-3-carboxamide 4a (NESS 0327) (Ruiu, S.; Pinna, G. A.; Marchese, G.; Mussinu, J. M.; Saba, P.; Tambaro, S.; Casti, P.; Var

Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same

The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula: in which R1 represents a C3-C15 carboxyl radical or an NR2R3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB1 receptors.

Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists.

The design, synthesis and biological activities of potent pyrazole-based tricyclic CB1 receptor antagonists (2) are described. The key synthetic step involves the ring closure of the lithiated alpha, gamma-keto ester adduct (4). The optimal nitroderivativ